Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zopolrestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.87 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.87 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.87 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zopolrestat SCHEMBL49012 | 0.93 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 0.93 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL29353641 | 0.93 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129027 | 0.92 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7185596 | 0.92 | AKR1B1 (0.90) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7179887 | 0.90 | AKR1B1 (0.87) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15939730 | 0.85 | AKR1B1 (0.84) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7565103 | 0.85 | AKR1B1 (0.84) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129830 | 0.85 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15939751 | 0.84 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212072-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2003-11-13 | — | — | US | claimed |
| US-6570013-B2 | (4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro -phthalazin-1-yl)-acetic acid ethanolamine salt, useful for treating diabetic complication in a mammal | PFIZER INC | 2003-05-27 | — | — | US | claimed |
| WO-2002098429-A1 | ETHANOLAMINE, DIETHANOLAMINE OR TRIETHANOLAMINE SALT OF ZOPOLRESTAT | PFIZER PRODUCTS INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | claimed |
| US-20030212072-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2003-11-13 | — | — | US | disclosed |
| US-6570013-B2 | (4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro -phthalazin-1-yl)-acetic acid ethanolamine salt, useful for treating diabetic complication in a mammal | PFIZER INC | 2003-05-27 | — | — | US | disclosed |
| WO-2002098429-A1 | ETHANOLAMINE, DIETHANOLAMINE OR TRIETHANOLAMINE SALT OF ZOPOLRESTAT | PFIZER PRODUCTS INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056095-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | AKR1B1 385/4885AKR1B10 636/4885AKR1A1 487/4885 |
| US-20030212072-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | AKR1B1 385/4885AKR1B10 636/4885AKR1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.